News|Articles|June 13, 2017

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-07-05-2017
  • Volume 12
  • Issue 7

Aptar Adds Nasal Pump Manufacturing Capacity

Aptar now manufactures its child-resistant pump, designed to meet US CPC requirements, at its facility in Congers, New York.

Aptar Pharma transferred equipment to manufacture its Child-Resistant and Senior-Friendly Classic Nasal Pump from its plant in southern Germany to its Congers, New York site, the company announced on June 12, 2017. The move, which took place in April 2017, brought manufacturing capacity closer to the US target market for the pump. The child-resistant technology was developed primarily for the US market when, in 2012, the US Consumer Product Safety Commission issued a rule requiring child-resistant packaging for any over-the-counter or drug product containing the equivalent of 0.08 mg or more of imidazoline, a formulation widely used in nasal decongestant topical sprays.

The company had also expanded manufacturing capacity at the Congers site for injection molding of elastomeric components, such as stoppers for parenteral containers, in March 2017.

Source: Aptar Pharma


Related to this article

white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Green Chemistry Supply and Demand in Sustainable Pharma
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.